Aortyx, a CataloniaBio & HealthTech member, has received a grant of 2.5 million euros from the European Commission, part of the EIC Accelerator program, that supports SMEs to scale up high impact innovations with the potential to create new markets or disrupt existing ones.

The funds will be dedicated to advancing the preclinical phase of the first product of Aortyx, the preclinical studies and the necessary regulatory stages to initiate the clinical trials and develop the market access strategy. The company has developed a patch for the treatment of aortic dissections that adhere to the damaged artery and plug the wound. The technology mimics the original tissue, enhancing regeneration to increase the hope and quality of life of aortic dissection patients.

Aortyx was founded in October 2018 by Jordi Martorell, Noemí Balà, Salvador Borrós and Vicenç Riambau. The founders are researchers from the Sarrià Chemical Institute (IQS) and the Hospital Clínic Barcelona.

Photo: Noemí Balà and Jordi Martorell, co-founders of Aortyx, preparing for the Step 3 telematic Interview phase (picture from Aortyx)